
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is expected to have positive data results at ASCO later this month with their multi-cancer early detection test, which could lead to a potential FDA approval and favorable reaction from oncologists. Despite facing guidance conservatism due to uncertainties with their digital health partners and sales force ramp, the company has shown strong revenue growth and has a favorable risk/reward profile. The company also has a wide range of potential revenue outcomes, with the biggest factor being FDA approval.
Bears say
GRAIL is facing challenges in gaining adoption from major health systems due to potential workflow friction, and its reliance on self-pay customers may not be sustainable once FDA approval is obtained. Additionally, there are risks associated with potential FDA approval delays or a more limited label, as well as potential setbacks in obtaining Medicare reimbursement. Revenue estimates have been adjusted slightly, but a neutral outlook is maintained for the stock due to the potential for a premium multiple in the underpenetrated MCED market and expected volume growth.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares